ZIEXTENZO® (pegfilgrastim-bmez)
Payer Access

SELECT YOUR STATE TO VIEW YOUR COVERAGE
Select your state
Select your coverage type
Commercial Medicare Medicaid
Find my ZIEXTENZO coverage!  
Please see table below for updated coverage
based on your selection
Select your coverage type
Commercial Medicare Medicaid
Select your benefit type
Medical Pharmacy
Find my ZIEXTENZO coverage!
Please see table below for updated coverage
based on your selection
ZIEXTENZO Top 10 Plans
MEDICAL1
PHARMACY2
Learn more about the value of Sandoz biosimilars
References: 1. Data on file. Princeton, NJ: Sandoz Inc; April 2025. 2. Data on file. Princeton, NJ: Sandoz Inc; April 2025.

IMPORTANT SAFETY INFORMATION FOR ZIEXTENZO

CONTRAINDICATIONS

ZIEXTENZO is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.

WARNINGS AND PRECAUTIONS

Splenic Rupture

  • Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving ZIEXTENZO.

Acute Respiratory Distress Syndrome (ARDS)

  • ARDS can occur in patients receiving pegfilgrastim. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving ZIEXTENZO, for ARDS. Discontinue ZIEXTENZO in patients with ARDS.

Serious Allergic Reactions

  • Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim. The majority of events occurred upon initial exposure and can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue ZIEXTENZO in patients with serious allergic reactions. Do not administer ZIEXTENZO to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.

Use in Patients with Sickle Cell Disorders

  • Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. Discontinue ZIEXTENZO if sickle cell crisis occurs.

Glomerulonephritis

  • Glomerulonephritis has occurred in patients receiving pegfilgrastim. The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events resolved after dose-reduction or discontinuation of pegfilgrastim. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose reduction or interruption of ZIEXTENZO.

Leukocytosis

  • White blood cell (WBC) counts of 100 x 109/L or greater have been observed in patients receiving pegfilgrastim. Monitoring of complete blood cell (CBC) count during pegfilgrastim therapy is recommended.

Thrombocytopenia

  • Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor platelet counts.

Capillary Leak Syndrome (CLS)

  • CLS has been reported after granulocyte colony-stimulating factor (G-CSF) administration, including pegfilgrastim, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed. Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include intensive care.

Potential for Tumor Growth Stimulatory Effects on Malignant Cells

  • The G-CSF receptor through which pegfilgrastim and filgrastim act has been found on tumor cell lines. The possibility that pegfilgrastim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim is not approved, cannot be excluded.

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer

  • MDS and AML have been associated with the use of pegfilgrastim in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS and AML in these settings.

Aortitis

  • Aortitis has been reported in patients receiving pegfilgrastim. It may occur as early as the first week after the start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and WBC count). Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue ZIEXTENZO if aortitis is suspected.

Nuclear Imaging

  • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results.

ADVERSE REACTIONS

The most common adverse reactions are bone pain and pain in extremity.

Please see ZIEXTENZO full Prescribing Information.

INDICATION FOR ZIEXTENZO

ZIEXTENZO is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

LIMITATIONS OF USE

ZIEXTENZO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Build up your defense against infection with ZIEXTENZO.

ZIEXTENZO is a long-acting filgrastim biosimilar and is prescribed to patients receiving chemotherapy at risk of infection

Learn about ZIEXTENZO

What is ZIEXTENZO?

ZIEXTENZO is a biosimilar of Neulasta® that can help protect you from the risk of infection during chemotherapy.

Learn more
How to inject ZIEXTENZO

Learn how to inject ZIEXTENZO

ZIEXTENZO can be self-administered or administered by a caregiver. Find instructions for both methods here.

Watch the videos
Enroll in $0 co-pay*
ZIEXTENZO $0 Co-Pay Program

Enroll in $0 co-pay*

Eligible and commercially insured patients can enroll by phone or online.
 

Enroll now

*Eligibility Requirements: Maximum benefit of $10,000 annually. Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescription for ZIEXTENZO is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Co-Pay Program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Co-Pay Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

Neulasta is a registered trademark of Amgen Inc.

Important Safety Information

Do not take Ziextenzo® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Ziextenzo®, tell your healthcare provider about all of your healthcare conditions, including if you:

  • Have a sickle cell disorder
  • Have kidney problems
  • Are allergic to latex—The needle cap on the prefilled syringe contains dry natural rubber (made from latex).
  • Are pregnant or plan to become pregnant. It is not known if Ziextenzo® will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Ziextenzo® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible serious side effects of Ziextenzo®?

  • Spleen Rupture. Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.
  • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Ziextenzo® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating. If you have any of these symptoms, stop using Ziextenzo® and call your healthcare provider or get emergency medical help right away.
  • Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Ziextenzo®. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
  • Kidney injury (glomerulonephritis). Ziextenzo® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:
    • swelling of your face or ankles
    • blood in your urine or dark colored urine
    • urinate less than usual
  • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Ziextenzo®.
  • Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with ZIEXTENZO. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with ZIEXTENZO. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
  • Capillary Leak Syndrome. Ziextenzo® can cause fluid to leak from blood vessels into your body's tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
    • swelling or puffiness and are urinating less than usual
    • trouble breathing
    • swelling of your stomach area (abdomen) and feeling of fullness
    • dizziness or feeling faint
    • a general feeling of tiredness
  • Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when ZIEXTENZO is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with ZIEXTENZO.
  • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received pegfilgrastim. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Ziextenzo® is pain in your bones, arms, and legs.

These are not all the possible side effects of Ziextenzo®. Call your healthcare provider for medical advice about side effects. To report negative side effects, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is Ziextenzo?

Ziextenzo® is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.

Please see ZIEXTENZO full Prescribing Information  and  Patient Information.